Stemline names Eric Rowinsky CMO
This article was originally published in Scrip
Executive Summary
Stemline Therapeutics, a biopharma company developing novel oncology therapeutics that target cancer stem cells, has appointed Dr Eric Rowinsky executive vice-president, chief medical officer and head of R&D. Dr Rowinsky has more than 25 years' experience managing clinical trials and developing drugs from preclinical to regulatory approval, having previously served as executive vice-president and CMO for Imclone Systems where he led the FDA approval of Erbitux (cetuximab).